Jim Simons Exicure, Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.3 - $0.64 $15,210 - $32,448	-50,700 Reduced 77.29%	14,900 $4,000
Q1 2024 May 13, 2024	BUY	$0.53 - $0.84 $8,533 - $13,524	16,100 Added 32.53%	65,600 $39,000
Q4 2023 Feb 13, 2024	SELL	$0.37 - $0.75 $3,145 - $6,375	-8,500 Reduced 14.66%	49,500 $29,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.36 $3,479 - $6,664	-4,900 Reduced 7.79%	58,000 $42,000
Q2 2023 Aug 11, 2023	SELL	$0.85 - $1.44 $2,720 - $4,608	-3,200 Reduced 4.84%	62,900 $82,000
Q1 2023 May 12, 2023	SELL	$0.78 - $1.58 $4,290 - $8,690	-5,500 Reduced 7.68%	66,100 $58,000
Q4 2022 Feb 13, 2023	SELL	$0.71 - $9.3 $5,822 - $76,260	-8,200 Reduced 10.28%	71,600 $82,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $8.5 $29,215 - $162,307	-19,095 Reduced 19.31%	79,800 $125,000
Q2 2022 Aug 12, 2022	BUY	$2.16 - $6.36 $213,613 - $628,972	98,895 New	98,895 $214,000

287K

Ticker XCUR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,962,580
Market Cap $55.5M
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.